KLOW: what is and is not known about the blend
In short
KLOW is the product name of a peptide blend sold online, not a studied product: we know of no published study of the KLOW blend in humans, animals or cells. So there is no research evidence on its effects, safety or dosage.
- The name is not the name of a molecule but a product name. No regulator or research group has defined what KLOW contains.
- The composition declared by sellers is GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg in an 80 mg vial. The contents have not been tested by an independent laboratory, and the seller's declaration does not guarantee them [2]E, not peer-reviewed.
- A blend does not inherit the evidence of its parts, and even the parts have mostly animal and laboratory studies [4, 5].
- There is no approved dosage, because the product is not an approved medicine. Fimea warns against injectable peptides bought online [1]regulator.
What is KLOW?
The composition of the KLOW blend rests on sellers' declarations. The contents have not been tested by an independent laboratory, and no research or regulatory source defines what KLOW contains [2]E, not peer-reviewed.
KLOW is a product name for a mix of several peptides in the same vial, not the name of a single substance. On the product pages of five sellers (13 Oct 2026), all declared the same four parts and the same split in an 80 mg vial: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. The declared composition is thus the GLOW blend with KPV added [2]E, not peer-reviewed. The sellers are not named or linked.
This sets KLOW clearly apart from substances with their own molecular name, such as BPC-157, TB-500, GHK-Cu and KPV. A molecular name has an exact chemical definition and can be looked up in scientific databases. A product name has neither: it is defined by whoever sells the product.
In practice, two different vials called KLOW may hold different substances, different amounts or different ratios, and the buyer cannot tell from the label. On the general problem with blends: what blends are and why the seller's declaration is not enough. All blends: Blends. A blend from the same name family without KPV: GLOW.
Evidence at a glance
Each cell gives the kind of study and its source. The letter is the evidence level, not the result. Rows on the individual parts do not apply to the KLOW product.
| Claimed effect | Humans | Animals | Cells |
|---|---|---|---|
| The KLOW blend itself | None known to us | None known to us | None known to us |
| BPC-157 and TB-500 together | - | In rats no added benefit over either alone [3]C | - |
| BPC-157 (declared part) | Three small pilot studies [4] | Tissue repair in animal models [4] | - |
| TB-500 (declared part) | No human exposure data [7]regulator | In rats the repaired tendon withstood a higher load [3]C | - |
| GHK-Cu (declared part) | Small face cream studies, no injections [5] | Tissue renewal in animal studies [5] | - |
| KPV (declared part) | - | KPV added to drinking water reduced bowel inflammation in mice [8]C | - |
| Safety | No data on the blend; little human data on unapproved peptides [6] | - | - |
"-" = no study of this.
Has KLOW been studied in humans?
Not as far as we know (see In short above). The same applies to animal and cell studies and to case reports.
What is known about the individual parts
The following results concern the individual parts declared by sellers, not the KLOW product.
- BPC-157 and TB-500 together. In a rat study, the repaired Achilles tendons of 32 rats were treated for four weeks with BPC-157, TB-500, both, or nothing. In the TB-500 group the tendon withstood a higher load than in controls. The combination gave no added benefit over either alone [3]C. GHK-Cu and KPV were not included.
- BPC-157. According to a review, BPC-157 has had effects on tissue repair in animal models, but only three small pilot studies have been published in humans [4].
- GHK-Cu. According to a review, the randomised human studies are small and mostly concern face creams [5]. Results from a cream do not tell what happens when the substance is injected.
- KPV. KPV added to drinking water reduced bowel inflammation in mice [8]C. There are no human studies.
A blend does not inherit the evidence of its parts. Putting several substances in one vial is a question of its own, covering efficacy, safety and stability, which studies of the single substances do not answer.
Who studies the KLOW blend?
No one that we know of has published research on it (see above).
Who wrote this page: the editorial team
This page was written by the Molecular Recovery editorial team. The draft was made with the help of AI, and the claims were checked against the sources (AI policy). The page has not been medically reviewed. How we work: About us.
What side effects does KLOW have?
There is no research information on the side effects of the KLOW blend itself (see In short above).
This is not a reassuring answer: a lack of data does not mean there are no harms. It means nobody has measured them.
What users report. In the Reddit accounts we compiled (not research), 39 of 69 people (57%) reported some harm, most often: injection site pain, redness or lump (11, 16%), rash, itch or breakouts (6, 9%) and fatigue (5, 7%). People tend to post when something goes wrong, so this share does not tell how common harms are. The figures are about the KLOW blend as sold or as the writer named it, not about its single substances, and the blend's contents were not verified. 30 people (43%) used other substances at the same time. The harms in detail: KLOW blend user experiences.
Three general risks in every blend
- Uncertain doses. When one vial holds several substances, each is present in some amount the buyer does not know. If the blend is dosed "as one substance", the dose of each part is unknown.
- Interactions between the parts. Peptides can affect each other's stability in solution. This cannot be inferred from studies of the single substances.
- Lost traceability. If a symptom appears while using a blend, there is no way to know which substance caused it, because the exposure was to several at once.
Risks of the declared parts
- According to the FDA's assessment, BPC-157 and injectable GHK-Cu may carry a risk of immune reactions. For TB-500 the FDA found no human exposure data at all [7]regulator.
- According to a review, unapproved peptides carry a possibility of serious harm because human safety data are scarce [6].
- KPV, the part that sets KLOW apart from GLOW, has no human studies: the only study cited on this page is in mice [8]C. So nothing is known about its harms in humans.
- In injectable products, impurities such as endotoxins increase the risk of serious harm to health [1]regulator.
Side effects of peptides in general: side effects in studies.
What the evidence does not support
The evidence supports no effect claimed for the KLOW blend, because there is no evidence on the blend.
- The evidence does not support dosing instructions. The blend has no dose page of its own. There is no research basis for a daily dose, dosing charts or cycle length, and this site gives no dosing recommendations.
- The evidence does not support the idea that the blend works as well as or better than its parts separately. That has not been compared. In the only combination study of the parts, BPC-157 and TB-500 together gave no added benefit in rats [3]C.
- The evidence does not support the assumption that the safety of the blend follows from the safety of its parts.
- The evidence does not support the assumption that the vial holds the composition the seller declares. According to Fimea, an unauthorised product may contain a different substance from the one on the package [1]regulator.
Is KLOW legal in Finland?
The KLOW blend has no marketing authorisation in Finland, so it may not be sold or marketed as a medicine [1]regulator.
- Medicines list. In the Finnish medicines list (230/2025), BPC 157, TB-500 and GHK-Cu are named in Annex 1 A, which covers medicinal substance analogues and prohormones classified as medicines. The list does not name KPV [9]regulator.
- Fimea warning 29 Jun 2026. Fimea warned against injectable peptides bought online and advises buying medicines only from legal pharmacies. A "research use only" label means the product is not intended for humans [1]regulator.
- Overview. Peptides and the law in Finland. Bringing them back from travel: Travelling with peptides.
For a blend the "research use only" label means something extra: because the product name does not define the contents, the label does not even say what is in the product.
This is not legal advice. Disclaimer.
Is KLOW a doping substance?
Yes, if the vial holds what sellers declare. On WADA's 2026 Prohibited List, BPC-157 falls under class S0 (non-approved substances) and thymosin beta-4 and its derivatives, such as TB-500, under class S2. Both classes are prohibited at all times [10]regulator. KPV is not named on the WADA list, but it probably falls under class S0, which always prohibits substances without approval by any authority for human therapeutic use [10]regulator. In a blend, one prohibited part is enough.
How to assess a KLOW product?
A certificate of analysis for a blend is more demanding than one for a single substance, and that is exactly why its gaps are easiest to miss.
For a single peptide two things are enough in principle: liquid chromatography (HPLC) shows purity and mass spectrometry (MS) shows whether the molecule is the right one. How to read one: how to read a COA.
For a blend that is not enough. A valid certificate (COA) should report each part separately: which substance, how much and measured by which method. A single purity percentage for the whole vial says nothing, because in a blend an "impurity" may be another intended part. If the certificate has only one number, it is not a certificate for a blend.
The certificate says nothing about sterility, endotoxins, the stability of the parts together in solution or what happened to the product in transit [1]regulator. Handling: mixing and storage.
FAQ
What is the KLOW peptide?
The product name of a peptide blend sold online, not the name of a single molecule. We know of no published study of it, and no research or regulatory source we know of defines its composition. Sellers declare GHK-Cu, BPC-157, TB-500 and KPV as its parts [2]E, not peer-reviewed.
What is the KLOW dosage, daily dose or cycle length?
There is no studied dosage, daily dose or cycle length, because there is no research on the blend itself. No dosing chart can be derived from research, and this site gives no dosing recommendations.
What are the benefits of KLOW?
Unknown: there is no research evidence of benefits. Separate studies of the parts do not apply to the blend.
Does KLOW help hair?
Unknown: there is no research evidence on KLOW and hair.
Are there before and after results for KLOW?
Not peer-reviewed ones. This site does not show before and after comparisons, because single photos or experiences say nothing about cause and effect.
Do KLOW user accounts show what is in the product?
No. The composition sellers declare has not been tested by an independent laboratory [2]E, not peer-reviewed, so the accounts cannot show what the product contained. Individual accounts are not research results either.
What do users themselves report about the KLOW blend?
In the Reddit accounts of 69 people we compiled (not research), 32 (46%) reported some benefit and 39 (57%) some harm. The accounts are self-selected and prove neither that it works nor that it is safe: KLOW blend user experiences.
Is KLOW legal in Finland?
KLOW has no marketing authorisation in Finland, so it may not be sold or marketed as a medicine. Fimea has warned against using injectable peptides bought online [1]regulator. This is not legal advice.
Read the research yourself: sources
Every source opens the original publication or the regulator's page. The level shows what the source itself reports.
- Fimea. Fimea warns: do not use injectable peptides purchased online (29 Jun 2026). Fimea regulator
- Seller product pages for KLOW, 5 sellers, read 13 Oct 2026: all 5 declare GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg in an 80 mg vial. Sellers' own claims, not tested by an independent laboratory. Not linked: this site does not link to shops. E, not peer-reviewed
- Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37:822-837. PMID 42542926 C
- McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18:611-619. PMID 40789979 (review)
- Najafi N, et al. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026;9:269-293. PMID 42787770 (review)
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56:1921-1935. PMID 41966639 (review)
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA regulator
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID 18061177 C
- Finland. Lääkeluettelo (Fimea medicines list), 230/2025, section 1 and annexes 1 and 1 A. Finlex regulator
- World Anti-Doping Agency. 2026 Prohibited List. WADA regulator
Research status checked in PubMed and seller product pages read 13 Oct 2026; sellers are not named or linked. Sources for the parts and for Fimea, the FDA, Finlex and WADA are the same as on the GLOW and KPV pages.
Evidence levels: A = randomised human trial or meta-analysis · B = observational human study or case series · C = animal study · D = cell or laboratory study · E = not peer-reviewed · regulator = a regulator's assessment or decision, not research evidence. The marker official means official product information (summary of product characteristics or label); it is not research evidence. For a review, the level shows what kind of research the statement rests on. No level: statements that something has not been studied, reviews' interpretations, named hypotheses and the general rules in our certificate-of-analysis guide.
Content is general information about research, not medical advice. If you have symptoms, contact a healthcare professional.